Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.

Demers GW, Johnson DE, Tsai V, Wen SF, Quijano E, Machemer T, Philopena J, Ramachandra M, Howe JA, Shabram P, Ralston R, Engler H.

Cancer Res. 2003 Jul 15;63(14):4003-8.

2.

Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.

Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K.

Clin Cancer Res. 2008 Jun 15;14(12):3933-41. doi: 10.1158/1078-0432.CCR-07-4732.

3.

Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.

Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P, Yu DC.

Cancer Gene Ther. 2005 Aug;12(8):715-22.

PMID:
15832172
4.

Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.

Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, Yun CO, Jooss K.

Cancer Res. 2007 May 1;67(9):4399-407. Erratum in: Cancer Res. 2007 Jun 15;67(12):5998.

5.

Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.

Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke LM, Ganesh S, Hay C, Huang Y, Kaloss M, Marinov A, Phipps SS, Reddy PS, Shirley PS, Skripchenko Y, Xu L, Yang J, Forry-Schaudies S, Hallenbeck PL.

Cancer Gene Ther. 2004 Aug;11(8):555-69.

PMID:
15232601
6.

A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.

Wang X, Su C, Cao H, Li K, Chen J, Jiang L, Zhang Q, Wu X, Jia X, Liu Y, Wang W, Liu X, Wu M, Qian Q.

Mol Cancer Ther. 2008 Jun;7(6):1598-603. doi: 10.1158/1535-7163.MCT-07-2429.

7.

E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.

Wakayama M, Abei M, Kawashima R, Seo E, Fukuda K, Ugai H, Murata T, Tanaka N, Hyodo I, Hamada H, Yokoyama KK.

Clin Cancer Res. 2007 May 15;13(10):3043-50.

8.

A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.

Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.

Cancer Gene Ther. 2008 Mar;15(3):173-82. Epub 2007 Dec 21.

PMID:
18157145
9.

Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.

Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.

Clin Cancer Res. 2006 Nov 1;12(21):6523-31.

10.

Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.

Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A.

Clin Cancer Res. 2009 Sep 1;15(17):5396-403. doi: 10.1158/1078-0432.CCR-08-2571. Epub 2009 Aug 25.

11.

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.

Gene Ther. 2006 Jul;13(13):1010-20. Epub 2006 Mar 9.

PMID:
16525479
12.

Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R.

Mol Ther. 2010 Jul;18(7):1275-83. doi: 10.1038/mt.2010.79. Epub 2010 May 4.

13.

Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.

Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J, Nery J, Zepeda M, Maneval DC, Demers GW, Ralston R.

Clin Cancer Res. 2004 Nov 1;10(21):7199-206.

14.

Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.

Ren Z, Ye X, Fang C, Lu Q, Zhao Y, Liu F, Liang M, Hu F, Chen HZ.

Cancer Biol Ther. 2008 Feb;7(2):191-95. Epub 2007 Nov 3.

PMID:
18073525
15.

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.

Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.

Cancer Gene Ther. 2004 Mar;11(3):174-85.

PMID:
14726958
16.

Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.

Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM, Soeffker D, Federspiel MJ, Russell SJ.

Cancer Gene Ther. 2006 Aug;13(8):732-8. Epub 2006 Mar 10.

PMID:
16543921
17.

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ.

Mol Ther. 2006 May;13(5):938-46. Epub 2006 Feb 8.

PMID:
16469543
18.

Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.

Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL.

Cancer Res. 2007 Oct 1;67(19):9371-9.

19.

Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma.

He LF, Gu JF, Tang WH, Fan JK, Wei N, Zou WG, Zhang YH, Zhao LL, Liu XY.

J Gene Med. 2008 Sep;10(9):983-92. doi: 10.1002/jgm.1231.

PMID:
18618506
20.

Targeting gene-virotherapy of cancer and its prosperity.

Liu XY.

Cell Res. 2006 Nov;16(11):879-86. Review.

Items per page

Supplemental Content

Write to the Help Desk